Last reviewed · How we verify

Placebo oxycodone/acetaminophen tablets

Purdue Pharma LP · Phase 3 active Small molecule

Placebo oxycodone/acetaminophen tablets is a Small molecule drug developed by Purdue Pharma LP. It is currently in Phase 3 development for Control arm in clinical trials for opioid/acetaminophen combination pain relief.

This is a placebo formulation containing no active pharmaceutical ingredients, used as a control in clinical trials to establish the true efficacy of oxycodone/acetaminophen combination therapy.

This is a placebo formulation containing no active pharmaceutical ingredients, used as a control in clinical trials to establish the true efficacy of oxycodone/acetaminophen combination therapy. Used for Control arm in clinical trials for opioid/acetaminophen combination pain relief.

Likelihood of approval
58.3% vs 58.3% industry baseline
If approved by FDA: likely 2028–2030
Steps remaining: NDA/BLA submission
Confidence: High
Why this estimate
  • Baseline phase 3 → approval rate +58.3pp
    Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2028–2030
EMA EU 2029–2031 +0.7 yr
MHRA GB 2029–2031 +0.7 yr
Health Canada CA 2029–2032 +0.9 yr
TGA AU 2029–2032 +1.2 yr
PMDA JP 2029–2032 +1.5 yr
NMPA CN 2030–2033 +2.3 yr
MFDS KR 2029–2032 +1.4 yr
CDSCO IN 2029–2033 +1.8 yr
ANVISA BR 2030–2033 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic namePlacebo oxycodone/acetaminophen tablets
SponsorPurdue Pharma LP
ModalitySmall molecule
Therapeutic areaPain Management
PhasePhase 3

Mechanism of action

Placebo tablets are inert formulations designed to match the appearance and administration route of the active drug being tested. In Phase 3 trials, placebos serve as the control arm to distinguish genuine pharmacological effects of oxycodone (an opioid analgesic) and acetaminophen (an analgesic/antipyretic) from placebo response and natural disease progression.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Placebo oxycodone/acetaminophen tablets

What is Placebo oxycodone/acetaminophen tablets?

Placebo oxycodone/acetaminophen tablets is a Small molecule drug developed by Purdue Pharma LP, indicated for Control arm in clinical trials for opioid/acetaminophen combination pain relief.

How does Placebo oxycodone/acetaminophen tablets work?

This is a placebo formulation containing no active pharmaceutical ingredients, used as a control in clinical trials to establish the true efficacy of oxycodone/acetaminophen combination therapy.

What is Placebo oxycodone/acetaminophen tablets used for?

Placebo oxycodone/acetaminophen tablets is indicated for Control arm in clinical trials for opioid/acetaminophen combination pain relief.

Who makes Placebo oxycodone/acetaminophen tablets?

Placebo oxycodone/acetaminophen tablets is developed by Purdue Pharma LP (see full Purdue Pharma LP pipeline at /company/purdue-pharma-lp).

What development phase is Placebo oxycodone/acetaminophen tablets in?

Placebo oxycodone/acetaminophen tablets is in Phase 3.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing